Cancer Biomarkers and Oncoviruses

Häftad, Engelska, 2025

3 651 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Cancer Biomarkers and Oncoviruses examines the extensive clinical applications of biomarkers in cancer research, with a particular focus on oncoviruses. The book explores key topics such as cancer risk assessment, screening, and early detection. It further covers accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring. In 47 detailed chapters, Cancer Biomarkers and Oncoviruses presents the molecular biology and pathogenesis of viral oncology, the mechanisms of viral oncogenesis in humans, signaling pathways, and therapeutic options such as vaccines. It also discusses the future of cancer therapy involving oncoviruses.
The present book also covers critical analyses of cost savings in healthcare, respiratory biomarkers in viral infections, and lessons learned from the COVID-19 pandemic, focusing on pandemic preparedness, early detection, surveillance, and response strategies. These discussions aim to provide valuable insights into how lessons from the pandemic can be applied to improve healthcare systems and response strategies for both viral infections and cancer, helping inform future health management practices.

This book is an invaluable resource for health professionals, scientists, researchers, health practitioners, students, and anyone seeking to deepen their understanding in the field of cancer and virology. It offers valuable state-of-the-art insights, incorporating the latest research and cutting-edge developments in the field.

Provides current, systematic scientific information on oncoviruses, including the molecular characteristics of cancers associated with these viruses, along with recent diagnostic and treatment strategies, and future perspectives in the field
Addresses key topics in tumor science by offering a comprehensive overview of cancers, covering diagnosis, cellular mechanisms, and therapeutic approaches
Incorporates critical analyses and lessons learned from the COVID-19 pandemic, focusing on pandemic preparedness, early detection, surveillance, and response strategies, providing insights that can be applied to cancer research and healthcare management
Offers up-to-date and comprehensive information to support informed decision-making regarding cancer diagnosis, treatment, and research, while also helping to shape future healthcare practices

Produktinformation

Utgivningsdatum:2025-12-10
Mått:191 x 235 x undefined mm
Vikt:1 770 g
Format:Häftad
Språk:Engelska
Antal sidor:900
Förlag:Elsevier Science
ISBN:9780443302251

Utforska kategorier

Onkologi inom Medicin
Patologi inom Medicin

Mer om författaren

Dr. Moulay Mustapha Ennaji, Professor in Virology and Oncology at the University of Casablanca and Director of the Quality and Medical Biotechnologies Team at Laboratory of Virology Microbiology, Hassan II University Mohammedia of Casablanca, Morocco He is currently a Professor in Virology and Oncology at the University of Casablanca, and since 2010, he has been the Director of the Quality and Medical Biotechnologies Team at the Laboratory of Virology Microbiology, Quality, Biotechnologies. He received a MSc in 1986 and a PhD in virology in 1993 from Armand Frappier Institute, University of Quebec (Canada). He has published dozens of journals articles and is an editorial board member of the journal, Infectious Agents and Cancer. Throughout his career, Dr. Ennaji has been rewarded several awards. At present, he is the vice president of the three Moroccan societies of Biosafety, Cancer, and Microbiology.

Innehållsförteckning

Part 1 Cancers: genetic insights, molecular mechanisms, and emerging therapiesChapter 1: Breast cancer and new methods for treatmentChapter 2: The role of genetic markers P53, BRCA1, and BRCA2 in breast cancer risk assessment in womenChapter 3: MicroRNAs as key regulators of hormone dependent pathways in breast cancerPart 2 Lung and prostate cancer: genetic abnormalities and biomarkersChapter 4: Genetic abnormalities of the EGFR pathway in the Middle East and North African patients with non-small cell lung cancerChapter 5: MicroRNAs: advances in biomarkers, diagnostics, and therapeutic strategies in prostate cancerPart 3 HPV and cervical cancer: screening, prevention, and molecular mechanismsChapter 6: Human papillomavirus infections in cervical cells for cervical cancer screeningChapter 7: MicroRNA and human herpesvirus 8 oncovirus in prostate cancerPart 4 Vitamin D and immune modulation in cancerChapter 8: Prostate cancer antigen 3 as a diagnostic, prognostic, and therapeutic biomarker in prostate cancerChapter 9: Interaction of the vitamin D in cancer development and progressionPart 5 Emerging therapies and biomarkers in cancerChapter 10: Study of the role of microRNAs in epstein barr virus induced prostate carcinogenesisChapter 11: Addressing the burden of human papillomavirus-related cancers in North Africa: epidemiology, sociocultural barriers and prevention strategiesPart 6 Management of the COVID-19 pandemic: lessons learned, surveillance, and respiratory biomarkers in SARS-CoV-2 pathogenesisChapter 12: Management of the COVID-19 pandemic in Skhirate-Temara, Morocco: lessons in preparedness, surveillance, and rapid responseChapter 13: Respiratory biomarkers in the pathogenesis of SARS-CoV-2Part 7 Viral miRNAs and oncoviruses: diagnostic, prognostic biomarkers, and therapeutic implications in cancerChapter 14: Oncoviruses and cancer biomarkers: current and future perspectivesChapter 15: MicroRNAs in cancer development: biomarkers, functions and therapyChapter 16: Viral miRNA’s: unlocking new frontiers in virus-induced cancersPart 8 Genetic and molecular basis of cancerChapter 17: Molecular alterations involved in lung cancerChapter 18: Oncogenic BRAF in prostate cancer: exosomes and miRNA status and implications for targeted therapyChapter 19: Targeted therapy in prostate and bladder cancer—role of BRAF and RAS mutationsChapter 20: In-depth analysis of tumor markers in leukemiaPart 9 Molecular mechanisms and therapeutic implications in cancerChapter 21: Nasopharyngeal cancer associated with epstein barr virusChapter 22: Molecular mechanisms of cervical cancerPart 10 Economic and market analysis in cancer researchChapter 23: Critical analysis of the cost savings generated by biomarkers and oncoviruses in healthcareChapter 24: Market analysis of exosome technologies for the diagnosis of genitourinary cancersPart 11 Phage therapy and immune modulationChapter 25: Phagotherapy: The discreet power of our immune cellsPart 12 Emerging therapies and biomarkers in cancerChapter 26: Mechanism of resistance to platinum salt-based chemotherapyChapter 27: Marine algae as a source of bioactive compounds: unlocking anticancer potentialChapter 28: Cervical cancer: new treatment approaches using microRNAChapter 29: Therapeutic potential of the intratumoral microbiota in tumorsChapter 30: Molecular biomarkers in bladder cancer: identification and clinical relevanceChapter 31: Emerging biomarker applications for precision targeting in bladder cancer therapyChapter 32: Fusion gene and cancerChapter 33: Immunotherapy biomarkers in melanoma: fromprogrammed death-ligand 1 expression to tumor mutational burdenChapter 34: The role of vitamin D supplementation in cancer treatmentChapter 35: The role of vitamin D in modulating immune responses against oncoviruses human papillomavirus, Epstein–Barr virus, and human herpesvirus-8Part 13 Epigenetics and DNA methylation in cancerChapter 36: Post-transcriptional epigenetic marks: DNA and microRNA methylationChapter 37: Epigenetic mechanism induced by human herpesvirus 8 in prostate cancerChapter 38: Role of methylation DNA in cell regulationChapter 39: DNA methylation biomarkers in colorectal cancerPart 14 Oncoviruses and viral-associated cancersChapter 40: Deciphering the molecular tapestry: extracellular vesicles as pioneering biomarker reservoirs for precision therapy in urogenital cancersChapter 41: Retroviruses as biomarkers in prostate carcinomaChapter 42: The role of breast cancer gene 1 and breast cancer gene 2 in determining breast cancer therapyChapter 43: The biomarkers landscape in lung cancer: implication for diagnosis, prediction, and prognosisChapter 44: Human papillomavirus as the main cause of cervical cancer: diagnosis, treatment, and preventionChapter 45: Oncogenic role of proline-rich protein 11 in breast and gynecologic cancers: mechanisms, signaling pathways, and therapeutic implicationsChapter 46: MicroRNAs as biomarkers in gynecological-mammary cancersChapter 47: Proline-rich protein 11 as a diagnosis and prognosis biomarker in breast and cervical cancersChapter 48: Recent advances in therapy and biomarkers: triple negative breast cancerChapter 49: Recent advances in exosome-based therapies for prostate cancer: targeting oncoviral and epigenetic pathwaysChapter 50: Exosomes as carriers of viral and host biomarkers in virus-associated gynecological cancers